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Abstract Though anti-metastatic function of non-metastatic
2 (NME2) has been implicated in multiple cancers, mecha-
nisms of metastases control by NME2 are not clearly under-
stood. Recent observations indicating the involvement of tel-
omerase, the ribonucleoprotein required for telomere synthe-
sis, in metastatic outcome are interesting. Notably, though the
role of telomerase dysfunction in tumorigenesis is relatively
well studied, involvement in metastasis progression is poorly
understood. Recent findings demonstrate NME2 presence at
telomere ends, association with telomerase, and NME2’s role
in inhibition of telomerase activity in cancer cells. These
present a novel opportunity to investigate mechanisms under-
lying NME2-mediated metastasis suppression.
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Role of non-metastatic 2 in suppression of cancer spread is
poorly understood
The non-metastatic factor 23 (Nm23) human isoform 2
(H2) also known as non-metastatic 2 (NME2) belongs to
the non-metastatic 23 gene family—the NME2 gene codes
for a 152-amino acid protein (∼18 kD) and is located on
chromosome 17q21.3. Multiple functions are reported for
NME2 including histidine kinase enzymatic activity, as-
sociation with proteins where the enzymatic function of
NME2 is not apparent and, interestingly, NME2 was also
found to influence gene expression (Desvignes et al.,
2009; Mehta and Orchard, 2009). Regulation of various
cellular processes in normal and/or cancer cells, such as
invasiveness and drug resistance by NME2 have been
studied (Hippe et al., 2003; Srivastava et al., 2006a; Di
et al., 2010a; Thakur et al., 2015; Yadav et al. 2014) and
in some cases, demonstrated in rodent and zebra fish
(Desvignes et al., 2011; Boissan and Lacombe, 2011;
Wieland, 2007). Role in transcription was implicated on
identification of NME2 as a purine nucleotide binding
factor involved in expression of the proto-oncogene c-
MYC (Berberich and Postel, 1995; Hildebrandt et al.,
1995; Postel et al., 1993; Postel and Ferrone, 1994).
Further work using chromatin-immunoprecipitation stud-
ies demonstrated NME2 physically occupies the c-MYC
promoter within cells (Thakur et al., 2009). In addition,
NME2 was found in the OCA-S multi-subunit co-
activator complex present on the histone 2B promoter
(Zheng et al., 2003); NME2-dependent histidine kinase
activity in human cells was a key factor in phosphorylation of
the KCa3.1 ion channel in CD4+ T lymphocytes; mice devoid
of NME2 (knockout) had impaired KCa3.1 function (Di et al.,
2010b; Srivastava et al., 2006b); and a ternary complex com-
prising NME2, ICAP1-alpha, and Lbc was observed to op-
pose cell migration (Iwashita et al., 2004). Moreover, the role
of NME1 as a close homologue was reported in DNA damage
and genome stability—studies by Kaetzel et al. found cells
with a mutant form of NME1 devoid of 3 -5 exonuclease
activity had altered metastatic proclivity compared to wild-
type cells (Kaetzel et al., 2006a). Consistent with this obser-
vation, treatment of cells with DNA-damaging agents resulted
in increased nuclear translocation of NME1 suggesting a
possible role in DNA repair (Novak et al., 2011; Kaetzel
et al., 2006b). Similar observations were reported in the yeast,
Saccharomyces cerevisiae where ablation of the NME
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homologue YNK1 delayed DNA damage response (Yang
et al., 2009).
Although a number of different roles of NME2 have been
described, somewhat surprisingly given the clinical implica-
tions, mechanisms of NME2 and metastasis suppression re-
mains poorly understood. Particularly, functions of NME2
with potential to control aggressive growth of cancer cells
needs further study (Thakur et al., 2011). Herein we focus
on an emerging aspect where NME2-mediated metastases
suppression could involve the human ribonucleoprotein
telomerase.
Telomere and telomerase: connection with tumor cells
Although cytogenetic studies in maize by Barbara McClin-
tock in 1931 first noted the “natural ends” of chromosome,
these were termed as telomere by Hermann Muller, and inde-
pendently by J.B.S. Haldane in 1938 (reviewed in (Blackburn
et al., 2006)). Interestingly, the importance of telomeres was
fully realized when it became evident that replication of
telomeric DNA by conventional DNA polymerases was not
possible (Blackburn, 1991). Two major lines of thought
emerged to address the replication problem associated with
telomere elongation. It was proposed to rely either on recom-
bination events between telomeres or on the existence of a
novel enzymatic activity that could synthesize telomere re-
peats de novo. Discovery of the ribonucleo-protein complex
telomerase comprising reverse transcriptase (TERT (Greider
and Blackburn, 1985)) and RNA motif (TERC (Chen and
Greider, 2004; Lingner and Cech, 1996)) with DNA polymer-
ase activity at telomeres supported the second point. On the
other the hand, in some tumor cell lines, a recombination-
based mechanism was found to maintain and elongate telo-
meres in the absence of telomerase—this was termed as
alternative lengthening of telomeres (ALT) (Bryan et al.,
1997).
Interestingly though, most eukaryotes use telomerase to
maintain telomeres (Greider and Blackburn, 1987) adult so-
matic tissues do not have sufficient telomerase activity
(Collins and Mitchell, 2002) and, therefore, accumulate chro-
mosomal damage at telomeres with age (Herbig et al., 2006)
(Blasco, 2007; Harley et al., 1992). In contrast, activation of
the telomerase gene in many tumors results in maintenance
and/or in some cases, elongation of telomeres thereby contrib-
uting to cell proliferation and tumorigenicity (Shay and
Wright, 2006) (Blasco, 2007).
Telomeres, telomerase and cancer spread (metastasis)
Though genomic instability due to altered telomere length and
telomerase reactivation are now established steps in
development and maintenance of tumor cells (Artandi et al.,
2000) (Artandi and Depinho, 2010), the connection between
telomerase activity/telomere length and metastasis (spread of
tumor cells to distant secondary organ sites) is not clearly
understood. One of the earliest correlations was from Griffith
et al.: reduced telomeric DNA content was found to correlate
with genomic instability and metastasis in invasive human
breast carcinoma (Griffith et al., 1999). In a recent study,
authors examined head and neck squamous cell carcinoma
(HNSCC) cells in a telomerase-deficient (made by genetically
knocking out Terc, the RNA component of telomerase) mu-
rine background with either long or short telomeres—G1 Terc
−/− telomerase-deficient mice with long telomeres, compared
to G5 Terc−/− telomerase-deficient mice with short telomeres,
had fewer lymph nodemetastases (Bojovic and Crowe, 2011).
Interestingly, authors also noted the initial loss of telomerase
activity in primary HNSCC resulted in reduced metastasis
(that is in G1 Terc−/− mice) whereas during later generations,
short telomeres (due to lack of telomerase activity) promoted
metastasis in G5 Terc−/− mice. Another study from the same
group characterized neu proto-oncogene driven mammary
tumor formation in G1 Terc−/− and G3 Terc−/− (telomerase
deficient with short telomeres), and Terc+/+ mice. Like the
earlier study, short telomeres dramatically increased lung me-
tastasis (Bojovic and Crowe, 2013).
Direct correlation between telomerase activity, hTERT
levels and cellular invasion was found when ribozyme-
mediated suppression of telomerase RNA (TER) levels in
melanoma cells resulted in reduced telomerase activity and
decreased invasive potential of melanoma cells (Bagheri et al.,
2006). Furthermore, it was observed that TER suppression
results in down-regulation of the glycolytic pathway and
reduced glucose metabolism provided a possible basis for
reduced metastatic potential. Consistent with this, Yu et al.
reported introduction of the full-length complementary DNA
(cDNA) of human telomerase gene hTERT into a telomerase-
negative osteosarcoma cell line U2OS (hTERT/U2OS) in-
creased invasive ability of cells. As expected, telomere length
in hTERT/U2OS cells was longer than that in vector control or
un-transfected U2OS cells (Yu et al., 2009).
In addition, a large pool of clinical data became available
where telomerase level correlated with progression of several
types of cancer including acute leukemia, breast, prostate,
lung and melanoma (Artandi and Depinho, 2010). A recent
meta-analysis of Lu et al. revealed high telomerase activity
was associated with the presence of lymph node metastasis,
depth of invasion, distant metastasis, tumor size, and metasta-
tic stage in gastric cancer (Lu et al., 2012). Another study
reported 63 of 71 breast cancer tissues with telomerase activity
(88.7 %) while no telomerase activity was detected in their
paired normal tissues (Rha et al., 1999); interestingly, telome-
rase activity correlated with node metastasis and stage, but not
tumor size or hormonal status of receptors. Comparison of
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telomerase activity and hTERT mRNA (hTERT) expression
in cancerous and non-cancerous lung tissues of 62 lung cancer
patients also revealed high telomerase activity and hTERT
levels in cancer tissues relative to non-cancerous tissues (Hara
et al., 2001). Furthermore, both telomerase activity and
hTERT expression significantly correlated with lymph node
metastasis (P<0.05). This study also noted that patients with
hTERT-positive tumor survived for a significantly shorter
period than those with hTERT-negative tumor (P=0.0334)
(Hara et al., 2001).
Taken together, an apparent contrast emerges. Loss of
telomerase activity promoted metastasis in breast and head
and neck cancer where absence of the telomerase RNA com-
ponent led to catalytically inactive telomerase (Terc−/−mice).
Whereas other studies, including clinical data, suggest low
telomerase activity imparts decreased metastatic potential.
These suggest a clear need for further work to understand
underlying mechanisms that govern links between telomerase
levels or activity and metastatic outcomes.
NME2-mediated metastasis—emerging connection
with telomerase function
Given the complexity noted in studies discussed above newly
observed NME2 function and its impact on telomerase activ-
ity are of interest. There are several reports related to involve-
ment of NME2 in metastasis (Bodey et al., 1997; Miyazaki
et al., 1999; Steeg et al., 1988; Thakur et al., 2011). NME2
expression was found to negatively correlate with advanced/
metastatic stages across several tumor types (Thakur et al.,
2011). Surprisingly, analysis of short sequence reads from
chromatin immunoprecipitation of NME2 in A549 cells
followed by massively parallel chromatin immunoprecipita-
tion sequencing (ChIP-seq) revealed a large number of se-
quences from telomere ends (Kar et al., 2012). We found
support for this unanticipated finding from earlier work
reporting in vitro association of NME2 with oligonucleotide
sequences representing human telomere ends (Nosaka et al.,
1998). The possibility of NME2 being involved in direct/
indirect association with telomere ends therefore presents a
novel opportunity to understand NME2 function in the con-
text of metastasis (Fig. 1).
Intracellular association of NME2 and telomeric DNAwas
clearly observed using chromatin immunoprecipitation (ChIP)
and experiments; co-immunoprecipitation experiments further
suggested physical interaction between NME2 and telomerase
in metastatic cancer cells (Kar et al., 2012). Furthermore,
direct physical association was observed using purified
hTERT and NME2 (Srivastava et al., 2014 unpublished).
Earlier studies suggested telomerase levels impact invasive-
ness of tumors (discussed earlier); therefore, reported involve-
ment of NME2 in metastasis prompted questions about role of
NME2with regard to telomerase activity. Notably, NME2was
found to not only associate with telomerase but also inhibit
telomerase activity in vitro as well as in cellulo (Kar et al.,
2012). In addition, it was also observed that inhibition of
telomerase activity in cells expressing elevated levels of
NME2 resulted in decrease in telomere length (Fig. 2).
Conclusion—a potential mechanistic model for further
work
Keeping in mind the poorly understood link between
telomerase (level and activity) and metastatic proclivity
of human cancer cells on one hand, NME2 functions
noted in metastasis control (Thakur et al., 2015; Yadav
et al. 2014) on the other hand, the emerging axis
between NME2 and telomerase activity is interesting.
Though results noted above suggest the role of NME2
in the suppression of telomerase activity, further work is
required to understand whether and how this impacts
metastasis. Based on current findings, a possible model
can be envisaged where NME2-telomerase interaction
impacts telomerase both catalytically and non-catalyti-
cally. Whereas decreased catalytic activity is bound to
influence telomere length directly resulting reduction in
metastatic potential is also possible as reported in some
tumors (Bagheri et al., 2006; Saito et al., 1997). Some-
what surprisingly, a recent finding showed extra-
telomeric binding of telomerase at gene promoters.
Fig. 1 Effect of NME2 on
telomerase activity could be of
interest in relation to metastasis
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Authors further demonstrated that resultant activation
wnt-beta catenin genes increased the aggressiveness of
cells suggesting a non-catalytic function of telomerase
that impacts metastasis (Park et al., 2009). Considering
the role of NME2 in this context is interesting: NME2-
telomerase association and its effect, if any, on
telomerase-mediated activation of wnt-beta catenin sig-
naling could be a possible mode of influencing aggres-
sive potential of cells. Further work that tests these
possibilities, particularly the underlying mechanisms in
the light of multiple reported functions of NME2 like
histidine kinase activity, transcription regulation and role
in DNA damage, is therefore expected to impact our
understanding of metastasis in important ways.
Material and method
RT-PCR for hTERT and NME2
RNAwas extracted using TRIzol reagent (Sigma, USA) as per
manufacturer protocol. Complementary DNA was synthe-
sized using cDNA synthesis kit (Applied Biosystems,
Fig. 2 Stable expression of NME2 leads to reduced telomerase activity
and telomere shortening. RT-PCR (a) and western blot (b) for stable
expression of GFP-tagged NME2 in MDAM B-231 cells. c Telomerase
activity in GFP-NME2 cells using real time quantification of telomerase
activity; *P<0.05. d Southern blot analysis of stable GFP-NME2
MDAMB-231 cells to check telomere length compared to vector trans-
formed cells
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GMBH) following the manufacturer’s instructions. Transcript





Antibodies and western blotting
For western analysis, cell lysate were prepared using 1X Cell
culture lysis reagent (Promega) and were separated by SDS-
PAGE and transferred to polyvinylidene difluoride mem-
branes (Immobilon FL, Millipore); following primary and
secondary antibodies were used for immuno-blotting. Primary
antibodies anti-GFP antibody and secondary antibodies anti-
mouse alkaline phosphates conjugated were from Sigma.
Analysis of telomerase activity
Cells were lysed in a lysis buffer and telomerase-containing
fraction was prepared for real time telomerase activity assay
using quantitative telomerase detection kit (US Biomax,
USA) according to the manufacturer’s protocol. For stable
cells with sustained NME2 or empty vector expression (con-
trol cells) equal amount of lysate was taken and further used
for the assay as mentioned above. All assays were performed
in triplicate and relative fold-change in expression was calcu-
lated from observed Ct values.
Terminal restriction fragment length analysis
Measurements of telomere lengths were done as described
previously (van, SB. and de, LT 1997; Aubert et al.,
2012). Briefly, DNA was isolated and was digested to
completion with multiple restriction enzyme mix (∼1 U/
μg each of HinfI and RsaI, Roche Boehringer Mannheim,
Indianapolis, IN). The digested DNA was separated on a
0.7 % agarose gel in 0.5X Tris-borate EDTA [0.5 mol/L
Tris-borate (pH 8.3), 10 mmol/L EDTA]. The gel was
denatured for 20 min in 0.5 mol/L NaOH/1.5 mol/L NaCl,
rinsed with distilled H2O for 10 min, dried on Whatman
No. 3MM paper under vacuum for 1 h at 55 °C, and
neutralized for 15 min in 1.5 mol/L NaCl, 0.5 mol/L
Tris–HCl (pH 8.0). The gel was probed with a radio-
labeled telomeric probe for 16 h at 42 °C in 5X SSC
buffer, 5X Denhardt’s solution, 10 mmol/L Na2HPO4,
and 1 mmol/L Na2H2P2O7. The gel was then washed
once for 20 min in 2X SSC, twice for 15 min each in
0.1X SSC at room temperature, and exposed to a phos-
phor screen (PhosphorImager).
Invasion assay
A modified version of the Boyden chamber assay (Cell bio
Labs CytoSelect™) was used to determine the invasion po-
tential of cells as per manufacturer’s instructions (also de-
scribed earlier (Thakur et al., 2015)). Briefly, following sus-
pension in serum-free media (∼half-million cells/ml) cells
were incubated (24 h) for invasion assays in chambers pre-
coated with specialized membrane comprising constituents of
the extracellular matrix purified from mouse sarcoma tissue.
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